Thursday, 15 October 2026European Markets

EXPLOSIFS PROD.CHI Stock Rises By 24% In The Last 10 Sessions

Loading stream...

(vianews) - shares of explosifs prod.chi (cac 40: expl.pa) jumped by a staggering 24.32% in 10 sessions from €92.5 to €115.00 at 20:52 est on tuesday, after two consecutive sessions in a row of losses. cac 40 is rising 0.43% to €7,215.58, following the last session's upward trend.

about explosifs prod.chi

epc groupe engages in the manufacture, storage, and distribution of explosives in europe, africa, asia pacific, and the americas. the company also provides drilling and mining services; logistics services; and demolition services, including mechanical demolition, deconstruction and blasting of buildings, waste management, and asbestos removal. in addition, it produces 2-ethylhexyl nitrate, a diesel fuel additive that reduces emissions and enhances diesel engine performance. it serves customers operating in the mining, cement, aggregates, civil engineering, and defense industries. epc groupe was founded in 1893 and is headquartered in paris, france. epc groupe is a subsidiary of ste e.j. barbier.

earnings per share

as for profitability, explosifs prod.chi has a trailing twelve months eps of €4.92.

pe ratio

explosifs prod.chi has a trailing twelve months price to earnings ratio of 23.37. meaning, the purchaser of the share is investing €23.37 for every euro of annual earnings.

volatility

explosifs prod.chi's last week, last month's, and last quarter's current intraday variation average was 4.52%, 1.39%, and 1.92%.

explosifs prod.chi's highest amplitude of average volatility was 6.25% (last week), 2.62% (last month), and 1.92% (last quarter).

volume

today's last reported volume for explosifs prod.chi is 64 which is 40.15% below its average volume of 254.

more news about explosifs prod.chi (expl.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com